Presbyopia Drug Adoption Risks May Limit Returns Yet Long-Term Demand Should Still Support Upside

Catalysts

About LENZ Therapeutics

LENZ Therapeutics develops and commercializes ophthalmic therapies, including VIZZ, a pharmacologic eye drop for the treatment of presbyopia in adults.

What are the underlying business or industry changes driving this perspective?

• Although presbyopia represents a very large and growing population of over 100 million adults who increasingly seek non-surgical, lifestyle-friendly vision solutions, LENZ must still prove that this new drug category can sustain broad, repeat use beyond early adopters. This will determine whether prescription volumes can scale to the level needed to materially lift long-term revenue.
• While the early commercial metrics for VIZZ, including high eye care professional awareness and rapid initial prescription uptake, point to a differentiated product profile, the company is heavily reliant on a single asset in a nascent category. This leaves earnings highly exposed if real-world adherence, refill rates or tolerability issues limit durable market penetration.
• Although partnerships in large international markets such as China and Canada expand the potential reach of VIZZ and provide milestone and royalty opportunities, execution risk around local regulatory processes, partner commercialization quality and pricing dynamics could delay or constrain the anticipated contribution to overall revenue growth.
• While LENZ has built a sizable sales infrastructure and is preparing a high-impact digital direct-to-consumer campaign anchored by a well-known spokesperson, there is a risk that escalating commercial and marketing spend outpaces the ramp in prescriptions. This could pressure operating leverage and delay the path to improved net margins.
• Despite a bolstered cash position that currently supports investment through the early launch period, future manufacturing scale-up, ongoing promotional intensity and potential competitive entrants may require continued high operating expenditure. This could suppress earnings and limit financial flexibility if revenue growth normalizes below current expectations.

Assumptions

This narrative explores a more pessimistic perspective on LENZ Therapeutics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming LENZ Therapeutics's revenue will grow by 117.0% annually over the next 3 years.
• The bearish analysts are not forecasting that LENZ Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate LENZ Therapeutics's profit margin will increase from -336.5% to the average US Pharmaceuticals industry of 20.9% in 3 years.
• If LENZ Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $37.3 million (and earnings per share of $0.97) by about December 2028, up from $-58.9 million today.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 47.6x on those 2028 earnings, up from -14.2x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 19.5x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The long-term sustainability of demand for pharmacologic presbyopia drops is unproven, and early enthusiasm from eye care professionals may not translate into broad, recurring adoption across the 128 million person presbyopia population. This would cap prescription volumes and limit long-term revenue growth.
• LENZ is currently a single product story. Any real world tolerability issues, such as higher than expected rates of redness or stinging, lower than anticipated refill behavior, or emerging safety concerns, could erode doctor confidence over time and materially pressure both revenue and future earnings.
• The commercial strategy relies on heavy, ongoing spend, including an 88 person field force, large sample volumes, and a high profile direct to consumer campaign. If these investments do not drive a proportional and durable lift in prescriptions, operating expenses could stay structurally high and delay the path to attractive net margins.
• Ex United States growth is dependent on partners navigating local regulatory and reimbursement environments in markets such as China and Canada. Slower than expected approvals, pricing pressure, or weaker partner execution would reduce anticipated milestone income and royalty streams, weighing on overall earnings power.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for LENZ Therapeutics is $37.91, which represents up to two standard deviations below the consensus price target of $53.5. This valuation is based on what can be assumed as the expectations of LENZ Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $62.0, and the most bearish reporting a price target of just $36.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2028, revenues will be $178.9 million, earnings will come to $37.3 million, and it would be trading on a PE ratio of 47.6x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $26.72, the analyst price target of $37.91 is 29.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.